Literature DB >> 6873549

[Chemotherapy of extensive digestive cancers with 5-fluorouracil: relation between the clinical response and plasma clearance of the drug].

J F Seitz, J P Cano, J P Rigault, C Aubert, Y Carcassonne.   

Abstract

This study was designed to establish a possible relationship between the pharmacokinetics of 5-FU and response to treatment. Thirteen patients with advanced, histologically proven malignancies of the gastrointestinal tract were studied. 5-FU, at a single weekly dose of 15 mg/kg, was given in bolus or as an 8-h infusion to every patient. Plasma clearance of 5-FU after an i.v. bolus injection of 15 mg/kg was individually determined and found to vary widely among patients (from 0.39 to 2.55 l/min). A clearance greater than or equal to 0.86 l/min was seen in all the patients who did not respond to treatment. All patients (except one) with a partial response or a stable disease had a clearance less than or equal to 0.72 l/min. The mean clearance of non-responders (1.40 +/- 0.21 l/min) was significantly greater (P less than 0.02) than that of partial responders or patients with stable disease (0.73 +/- 0.15 l/min). These preliminary results deserve further investigation on a larger number of patients, before plasma levels of 5-FU may be accepted as an indication of response to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6873549

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  9 in total

1.  Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6.

Authors:  Rajesh R Kaldate; Abebe Haregewoin; Charles E Grier; Stephanie A Hamilton; Howard L McLeod
Journal:  Oncologist       Date:  2012-03-01

2.  Relationship between systemic 5-FU passage and response in colorectal cancer patients treated with intrahepatic chemotherapy.

Authors:  G Milano; M Namer; J L Boublil; R Khater; M Frenay; A Thyss; J Bourry; C Philip; N Renée; J N Bruneton
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 3.  Pharmacokinetic optimisation of anticancer therapy.

Authors:  J Liliemark; C Peterson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

4.  Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer.

Authors:  A Thyss; G Milano; N Renée; J Vallicioni; M Schneider; F Demard
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 5.  Therapeutic drug monitoring of 5-fluorouracil.

Authors:  James J Lee; Jan H Beumer; Edward Chu
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-23       Impact factor: 3.333

6.  Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities.

Authors:  M Barberi-Heyob; B Weber; J L Merlin; C Dittrich; E A de Bruijn; E Luporsi; F Guillemin
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer.

Authors:  Takao Tamura; Akiko Kuwahara; Kaori Kadoyama; Motohiro Yamamori; Kohshi Nishiguchi; Tsubasa Inokuma; Yoshiji Takemoto; Naoko Chayahara; Tatsuya Okuno; Ikuya Miki; Yoshimi Fujishima; Toshiyuki Sakaeda
Journal:  Int J Med Sci       Date:  2011-07-01       Impact factor: 3.738

8.  A narrative review of genetic factors affecting fluoropyrimidine toxicity.

Authors:  William H Gmeiner
Journal:  Precis Cancer Med       Date:  2021-12-30

9.  Pharmacokinetics of continuous transarterial infusion of 5-fluorouracil in patients with advanced hepatocellular carcinoma.

Authors:  Jian Gao; Rui Zhen; Hai Liao; Wenquan Zhuang; Wenbo Guo
Journal:  Oncol Lett       Date:  2018-03-12       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.